Alkermes (ALKS) PT Lowered to $45 at BofA/Merrill Lynch; Sees Loss in 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Alkermes plc (ALKS) Phase 1 Study of ALKS 7106 Fails, Further Development Halted
February 24, 2015 7:05 AM ESTAlkermes plc (NASDAQ: ALKS) today announced topline results from a phase 1 clinical study of ALKS 7106, a new molecule intended for the treatment of pain. The randomized, double-blind, placebo-controlled study was designed to evaluate the safety, tolerability and pharmacokinetics of single escalating doses of ALKS 7106 in 64 healthy adults. Data from the study showed that ALKS 7106 did not meet... More
Alkermes plc (ALKS) Tops Q4 EPS by 7c; Guides FY15
February 24, 2015 7:03 AM ESTAlkermes plc (NASDAQ: ALKS) reported Q4 EPS of $0.11, $0.07 better than the analyst estimate of $0.04. Revenue for the quarter came in at $175.2 million versus the consensus estimate of $161.7 million.
Alkermes plc sees FY2015 EPS of $0.27-$0.40, versus the consensus of $0.20. Alkermes plc sees FY2015... More
